Investing.com - Eagle Pharm (NASDAQ: EGRX) reported second quarter EPS of $1.18, $0.11 better than the analyst estimate of $1.07. Revenue for the quarter came in at $64.6M versus the consensus estimate of $59.11M.
Guidance
Eagle Pharm sees Q3 2023 EPS of $4.40-$4.70 versus the analyst consensus of $4.48.
Eagle Pharm's stock price closed at $21.81. It is up 4.06% in the last 3 months and down -40.83% in the last 12 months.
Eagle Pharm saw 1 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Eagle Pharm's stock price’s past reactions to earnings here.
According to InvestingPro, Eagle Pharm's Financial Health score is "great performance".
Check out Eagle Pharm's recent earnings performance, and Eagle Pharm's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar